骨がん治療薬の世界市場2019-2023

◆英語タイトル:Global Bone Cancer Drugs Market 2019-2023
◆商品コード:IRTNTR31187
◆発行会社(リサーチ会社):Technavio
◆発行日:2019年4月12日
◆ページ数:125
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:グローバル、アジア、北米、ヨーロッパ(EMEA)
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD2,500 ⇒換算¥267,500見積依頼/購入/質問フォーム
Five User(5名様閲覧用)USD3,000 ⇒換算¥321,000見積依頼/購入/質問フォーム
Enterprise License(同一法人内共有可)USD4,000 ⇒換算¥428,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はTechnavio社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
Technavio社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

当調査レポートでは、骨がん治療薬の世界市場について調査・分析し、市場概要、市場環境、骨がん治療薬市場規模、疾患別(骨肉腫、ユーイング腫瘍、軟骨肉腫、その他)分析、市場動向、競争環境、主要地域別市場規模(北米、ヨーロッパ、アジアなど)、関連企業情報などを含め、以下の構成でお届け致します。
・エグゼクティブサマリー
・調査範囲・調査手法
・骨がん治療薬の世界市場概要
・骨がん治療薬の世界市場環境
・骨がん治療薬の世界市場動向
・骨がん治療薬の世界市場規模
・骨がん治療薬の世界市場:業界構造分析
・骨がん治療薬の世界市場:疾患別(骨肉腫、ユーイング腫瘍、軟骨肉腫、その他)
・骨がん治療薬の世界市場:地域別市場規模・分析
・骨がん治療薬の北米市場規模・予測
・骨がん治療薬のヨーロッパ・中東・アフリカ市場規模・予測
・骨がん治療薬のアジア太平洋市場規模・予測
・骨がん治療薬の主要国分析
・骨がん治療薬の世界市場:意思決定フレームワーク
・骨がん治療薬の世界市場:成長要因、課題
・骨がん治療薬の世界市場:競争環境
・骨がん治療薬の世界市場:関連企業情報(ベンダー分析)
【レポートの概要】

About this market
Increasing strategic alliance will drive the market growth in the forecast period. Small and medium sized pharmaceutical and biotechnology vendors in the market face lack of funding to complete clinical trial and launch the drugs for the treatment of various bone cancer indications. Pharmaceutical players face challenges with the distribution of drugs in the regions where the vendor does not operate. To overcome such challenge, these pharmaceutical companies are entering into strategic alliance with local pharmaceutical vendors for manufacturing and distribution of drugs. Technavio’ s analysts have predicted that the bone cancer drugs market will register a CAGR of nearly 12% by 2023.
Market Overview
Growing risk factors
Growing risk factors associated with bone cancer will drive the market growth in the forecast period. The growing prevalence of specific cancers, where radiation therapy has been a dominant treatment, is further stimulating the market growth. Factors such as old age and the family history of bone cancer are common risk factors for the disease.
Preference of surgery
The most preferred treatment options available to patients with bone cancer, is surgeries, due to their remissive nature. Surgery for bone cancer involves wide excision of the tumor, which includes removal of the tumor along with a part of healthy tissue around the tumor in all directions. The higher probability of recurrence of cancer tumors in the future reduces patient adherence to drug treatment landscape which poses a challenge to the market growth
For the detailed list of factors that will drive and challenge the growth of the bone cancer drugs market during the 2019-2023, view our report.
Competitive Landscape
The market appears to be concentrated and with the presence of few companies. Factors such as the growing risk factors and increasing strategic alliance, will provide considerable growth opportunities to bone cancer drugs manufactures. Amgenm, Bayer AG, Bristol-Myers Squibb Company, Merck & Co. Inc., and Pfizer Inc. are some of the major companies covered in this report.

【レポートの目次】

PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
• 2.1 Preface
• 2.2 Preface
• 2.3 Currency conversion rates for US$
PART 03: MARKET LANDSCAPE
• Market ecosystem
• Market characteristics
• Market segmentation analysis
PART 04: MARKET SIZING
• Market definition
• Market sizing 2018
• Market size and forecast 2018-2023
PART 05: FIVE FORCES ANALYSIS
• Bargaining power of buyers
• Bargaining power of suppliers
• Threat of new entrants
• Threat of substitutes
• Threat of rivalry
• Market condition
PART 06: PIPELINE
PART 07: MARKET SEGMENTATION BY INDICATION
• Market segmentation by indication
• Comparison by indication
• Osteosarcoma – Market size and forecast 2018-2023
• Ewing’s sarcoma – Market size and forecast 2018-2023
• Chondrosarcoma – Market size and forecast 2018-2023
• Others – Market size and forecast 2018-2023
• Market opportunity by indication
PART 08: CUSTOMER LANDSCAPE
PART 09: GEOGRAPHIC LANDSCAPE
• Geographic segmentation
• Geographic comparison
• North America – Market size and forecast 2018-2023
• Europe – Market size and forecast 2018-2023
• Asia – Market size and forecast 2018-2023
• ROW – Market size and forecast 2018-2023
• Key leading countries
• Market opportunity
PART 10: DECISION FRAMEWORK
PART 11: DRIVERS AND CHALLENGES
• Market drivers
• Market challenges
PART 12: MARKET TRENDS
PART 13: VENDOR LANDSCAPE
• Overview
• Landscape disruption
• Competitive scenario
PART 14: VENDOR ANALYSIS
• Vendors covered
• Vendor classification
• Market positioning of vendors
• Amgen
• Bayer AG
• Bristol-Myers Squibb Company
• Merck & Co. Inc.
• Pfizer Inc.
PART 15: APPENDIX
• Research methodology
• List of abbreviations
• Definition of vendors classification
PART 16: EXPLORE TECHNAVIO


Exhibit 01: Global oncology therapeutics market
Exhibit 02: Segments of global oncology therapeutics market
Exhibit 03: Market characteristics
Exhibit 04: Market segments
Exhibit 05: Market definition – Inclusions and exclusions checklist
Exhibit 06: Market size 2018
Exhibit 07: Global market: Size and forecast 2018-2023 ($ millions)
Exhibit 08: Global market: Year-over-year growth 2019-2023 (%)
Exhibit 09: Five forces analysis 2018
Exhibit 10: Five forces analysis 2023
Exhibit 11: Bargaining power of buyers
Exhibit 12: Bargaining power of suppliers
Exhibit 13: Threat of new entrants
Exhibit 14: Threat of substitutes
Exhibit 15: Threat of rivalry
Exhibit 16: Market condition – Five forces 2018
Exhibit 17: Global bone cancer drugs market pipeline: Overview
Exhibit 18: Global bone cancer drugs market pipeline: Snapshot
Exhibit 19: Indication – Market share 2018-2023 (%)
Exhibit 20: Comparison by indication
Exhibit 21: Osteosarcoma – Market size and forecast 2018-2023 ($ millions)
Exhibit 22: Osteosarcoma – Year-over-year growth 2019-2023 (%)
Exhibit 23: Ewing’s sarcoma – Market size and forecast 2018-2023 ($ millions)
Exhibit 24: Ewing’s sarcoma – Year-over-year growth 2019-2023 (%)
Exhibit 25: Chondrosarcoma – Market size and forecast 2018-2023 ($ millions)
Exhibit 26: Chondrosarcoma – Year-over-year growth 2019-2023 (%)
Exhibit 27: Others – Market size and forecast 2018-2023 ($ millions)
Exhibit 28: Others – Year-over-year growth 2019-2023 (%)
Exhibit 29: Market opportunity by indication
Exhibit 30: Customer landscape
Exhibit 31: Market share by geography 2018-2023 (%)
Exhibit 32: Geographic comparison
Exhibit 33: North America – Market size and forecast 2018-2023 ($ millions)
Exhibit 34: North America – Year-over-year growth 2019-2023 (%)
Exhibit 35: Top 3 countries in North America
Exhibit 36: Europe – Market size and forecast 2018-2023 ($ millions)
Exhibit 37: Europe – Year-over-year growth 2019-2023 (%)
Exhibit 38: Top 3 countries in Europe
Exhibit 39: Asia – Market size and forecast 2018-2023 ($ millions)
Exhibit 40: Asia – Year-over-year growth 2019-2023 (%)
Exhibit 41: Top 3 countries in Asia
Exhibit 42: ROW – Market size and forecast 2018-2023 ($ millions)
Exhibit 43: ROW – Year-over-year growth 2019-2023 (%)
Exhibit 44: Top 3 countries in ROW
Exhibit 45: Key leading countries
Exhibit 46: Market opportunity
Exhibit 47: Impact of drivers and challenges
Exhibit 48: Vendor landscape
Exhibit 49: Landscape disruption
Exhibit 50: Vendors covered
Exhibit 51: Vendor classification
Exhibit 52: Market positioning of vendors
Exhibit 53: Amgen – Vendor overview
Exhibit 54: Amgen – Business segments
Exhibit 55: Amgen – Organizational developments
Exhibit 56: Amgen – Geographic focus
Exhibit 57: Amgen – Key offerings
Exhibit 58: Amgen – Key customers
Exhibit 59: Bayer AG – Vendor overview
Exhibit 60: Bayer AG – Business segments
Exhibit 61: Bayer AG – Organizational developments
Exhibit 62: Bayer AG – Geographic focus
Exhibit 63: Bayer AG – Segment focus
Exhibit 64: Bayer AG – Key offerings
Exhibit 65: Bayer AG – Key customers
Exhibit 66: Bristol-Myers Squibb Company – Vendor overview
Exhibit 67: Bristol-Myers Squibb Company – Business segments
Exhibit 68: Bristol-Myers Squibb Company – Organizational developments
Exhibit 69: Bristol-Myers Squibb Company – Geographic focus
Exhibit 70: Bristol-Myers Squibb Company – Key offerings
Exhibit 71: Bristol-Myers Squibb Company – Key customers
Exhibit 72: Merck & Co. Inc. – Vendor overview
Exhibit 73: Merck & Co. Inc. – Business segments
Exhibit 74: Merck & Co. Inc. – Organizational developments
Exhibit 75: Merck & Co. Inc. – Geographic focus
Exhibit 76: Merck & Co. Inc. – Segment focus
Exhibit 77: Merck & Co. Inc. – Key offerings
Exhibit 78: Merck & Co. Inc. – Key customers
Exhibit 79: Pfizer Inc. – Vendor overview
Exhibit 80: Pfizer Inc. – Business segments
Exhibit 81: Pfizer Inc. – Organizational developments
Exhibit 82: Pfizer Inc. – Geographic focus
Exhibit 83: Pfizer Inc. – Segment focus
Exhibit 84: Pfizer Inc. – Key offerings
Exhibit 85: Pfizer Inc. – Key customers
Exhibit 86: Validation techniques employed for market sizing
Exhibit 87: Definition of vendors classification



【掲載企業】

Amgen, Bayer AG, Bristol-Myers Squibb Company, Merck & Co. Inc., Pfizer Inc.

【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[骨がん治療薬の世界市場2019-2023]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆